{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:06:00Z","timestamp":1791821160456,"version":"4.3.4"},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hepatic artery infusion chemotherapy (HAIC) has been used in efforts to improve outcomes in patients with locally advanced cholangiocarcinoma. Reported experiences are generally small institutional series. The efficacy of HAIC in locally advanced cholangiocarcinoma is not well defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a comprehensive search using the electronic databases PubMed, Embase, Cochrane, ClinicalTrials. Gov, and WHO Clinical Trials from inception to August 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 202 publications were screened, with 15 studies representing 588 patients meeting the inclusion criteria. Most patients demonstrated either a partial response or stable disease after therapy (CR: 2.5%, PR: 38.1%, SD: 43.4%, PD: 12.7%, NA: 3.3%). Meta\u2010analysis found a pooled median overall survival of 18.3 months (95% CI: 14.1\u201322.4 months) and progression\u2010free survival of 10.0 months (95% CI: 7.7\u201312.3 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HAIC demonstrates an improvement over reported survival for systemic chemotherapy alone when used as either an adjunct or in place of systemic therapy for first\u2010line treatment in patients with cholangiocarcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jso.70196","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:42:26Z","timestamp":1769499746000},"page":"465-474","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hepatic Artery Infusion Chemotherapy as a First\u2010Line Treatment in Unresectable Cholangiocarcinoma: A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1002","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3635-9595","authenticated-orcid":false,"given":"Noah","family":"Brown","sequence":"first","affiliation":[{"name":"Department of Surgery, Division of General Surgery University of Utah Health Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail J.","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of General Surgery University of Utah Health Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid M.","family":"Muhammed","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, College of Pharmacy University of Utah Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, College of Pharmacy University of Utah Salt Lake City Utah USA"},{"name":"IDEAS Center, Veterans Affairs Salt Lake City Healthcare System Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Scaife","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology Huntsman Cancer Institute Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology Huntsman Cancer Institute Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"issue":"5","key":"e_1_2_7_2_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100737","article-title":"Clinical Treatment of Cholangiocarcinoma: An Updated Comprehensive Review","volume":"27","author":"Elvevi A.","year":"2022","journal-title":"Annals of Hepatology"},{"issue":"6","key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the Diagnosis and Management of Intrahepatic Cholangiocarcinoma","volume":"60","author":"Bridgewater J.","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"6","key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma","volume":"145","author":"Ilyas S. I.","year":"2013","journal-title":"Gastroenterology"},{"issue":"2","key":"e_1_2_7_5_1","first-page":"198","article-title":"Advances in the Treatment of Intrahepatic Cholangiocarcinoma: An Overview of the Current and Future Therapeutic Landscape for Clinicians","volume":"73","author":"Moris D.","year":"2023","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"2","key":"e_1_2_7_6_1","first-page":"176","article-title":"Clinical Pharmacology of Hepatic Arterial Chemotherapy","volume":"10","author":"Ensminger W. D.","year":"1983","journal-title":"Seminars in Oncology"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.628558","article-title":"Meta\u2010Analysis of Hepatic Arterial Infusion for Liver Metastases From Colorectal Cancer","volume":"11","author":"Zhang Y.","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.suronc.2015.06.014","article-title":"Systematic Review and Meta\u2010Analysis of Hepatic Arterial Infusion Chemotherapy as Bridging Therapy for Colorectal Liver Metastases","volume":"24","author":"Chan D. L.","year":"2015","journal-title":"Surgical Oncology"},{"issue":"6","key":"e_1_2_7_9_1","first-page":"1499","article-title":"Combined\u2010Modality Treatment for Resectable Metastatic Colorectal Carcinoma to the Liver: Surgical Resection of Hepatic Metastases in Combination With Continuous Infusion of Chemotherapy\u2014An Intergroup Study","volume":"20","author":"Kemeny M. M.","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"27","key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJM199912303412702","article-title":"Hepatic Arterial Infusion of Chemotherapy After Resection of Hepatic Metastases From Colorectal Cancer","volume":"341","author":"Kemeny N.","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1085166","article-title":"Hepatic Arterial Infusion Chemotherapy Versus Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: An Updated Meta\u2010Analysis and Systematic Review","volume":"13","author":"Zhang W.","year":"2023","journal-title":"Frontiers in Oncology"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.597813","article-title":"High Response Rate and Prolonged Survival of Unresectable Biliary Tract Cancer Treated With a New Combination Therapy Consisting of Intraarterial Chemotherapy Plus Radiotherapy","volume":"10","author":"Goto T.","year":"2020","journal-title":"Frontiers in Oncology"},{"issue":"9","key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.3390\/cancers15092616","article-title":"The Effectiveness of the Combination of Arterial Infusion Chemotherapy and Radiotherapy for Biliary Tract Cancer: A Prospective Pilot Study","volume":"15","author":"Goto T.","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10147-011-0320-5","article-title":"A Phase I Trial of Arterial Infusion Chemotherapy With Gemcitabine and 5\u2010Fluorouracil for Unresectable Biliary Tract Cancer","volume":"17","author":"Hayashi T.","year":"2012","journal-title":"International Journal of Clinical Oncology"},{"issue":"1","key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5582\/bst.2017.01320","article-title":"Arterial Infusion of Cisplatin Plus S\u20101 Against Unresectable Intrahepatic Cholangiocarcinoma","volume":"12","author":"Higaki T.","year":"2018","journal-title":"BioScience Trends"},{"key":"e_1_2_7_16_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1260191","article-title":"Clinical and Biomarker Analyses of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and PD\u20101 Inhibitor for Patients With Advanced Intrahepatic Cholangiocarcinoma","volume":"15","author":"Huang Y.","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29824","article-title":"Unresectable Intrahepatic Cholangiocarcinoma: Systemic Plus Hepatic Arterial Infusion Chemotherapy Is Associated With Longer Survival in Comparison With Systemic Chemotherapy Alone","volume":"122","author":"Konstantinidis I. T.","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"578","DOI":"10.4103\/jcrt.jcrt_1549_23","article-title":"Hepatic Artery Infusion Chemotherapy With Systemic Capecitabine and Camrelizumab for Treating Unresectable Hilar Cholangiocarcinoma: An Initial Investigation of Efficacy and Safety","volume":"20","author":"Li L.","year":"2024","journal-title":"Journal of Cancer Research and Therapeutics"},{"issue":"6","key":"e_1_2_7_19_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00432-024-05795-2","article-title":"First\u2010Line Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and PD\u2010(L)1 Inhibitors Versus Systemic Chemotherapy Alone or With PD\u2010(L)1 Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma","volume":"150","author":"Lin Y. S.","year":"2024","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"e_1_2_7_20_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112872","article-title":"Hepatic Arterial Infusion of GEMOX Plus Systemic Gemcitabine Chemotherapy Combined With Lenvatinib and PD\u20101 Inhibitor in Large Unresectable Intrahepatic Cholangiocarcinoma","volume":"140","author":"Ni J.","year":"2024","journal-title":"International Immunopharmacology"},{"issue":"2","key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1148\/radiol.2016160572","article-title":"Phase II Study of Hepatic Arterial Infusion Chemotherapy With Oxaliplatin and 5\u2010Fluorouracil for Advanced Perihilar Cholangiocarcinoma","volume":"283","author":"Wang X.","year":"2017","journal-title":"Radiology"},{"issue":"2","key":"e_1_2_7_22_1","doi-asserted-by":"crossref","first-page":"Hep49","DOI":"10.2217\/hep-2023-0006","article-title":"Hepatic Arterial Infusion Chemotherapy With or Without Lenvatinib for Unresectable Cholangiocarcinoma: A Single\u2010Center Retrospective Study","volume":"10","author":"Wang Y.","year":"2023","journal-title":"Hepatic Oncology"},{"key":"e_1_2_7_23_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1235724","article-title":"Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib With or Without Programmed Cell Death Protein\u20101 Inhibitors for Advanced Cholangiocarcinoma","volume":"14","author":"Wei Z.","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"e_1_2_7_24_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1234342","article-title":"Comparison of Hepatic Arterial Infusion Chemotherapy With mFOLFOX vs. First\u2010Line Systemic Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma","volume":"14","author":"Yang Z.","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1397827","article-title":"Efficacy and Safety of Lenvatinib Plus Durvalumab Combined With Hepatic Arterial Infusion Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma","volume":"15","author":"Zhao R.","year":"2024","journal-title":"Frontiers in Immunology"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1097\/JS9.0000000000002013","article-title":"Hepatic Arterial Infusion Chemotherapy Plus Targeted Therapy and Immunotherapy Versus Systemic Chemotherapy for Advanced Intrahepatic Cholangiocarcinoma: A Retrospective Cohort Study","volume":"111","author":"Zheng Z.","year":"2024","journal-title":"International Journal of Surgery"},{"key":"e_1_2_7_27_1","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page M. J.","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"e_1_2_7_28_1","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.7861\/fhj.10-3-s26","article-title":"Assessing the Risk of Bias in Single\u2010Arm Trials for Systematic Reviews: Moving Towards a More Reliable Evaluation of Clinical Evidence","volume":"10","author":"Alsinbili A.","year":"2023","journal-title":"Future Healthcare Journal"},{"issue":"1","key":"e_1_2_7_29_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: Reconstruct Individual Patient Data From Published Kaplan\u2013Meier Survival Curves","volume":"21","author":"Liu N.","year":"2021","journal-title":"BMC Medical Research Methodology"},{"key":"e_1_2_7_30_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced Secondary Analysis of Survival Data: Reconstructing the Data From Published Kaplan\u2013Meier Survival Curves","volume":"12","author":"Guyot P.","year":"2012","journal-title":"BMC Medical Research Methodology"},{"issue":"15","key":"e_1_2_7_31_1","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1200\/jco.2013.31.15_suppl.4116","article-title":"Hepatic Arterial Infusion for Unresectable Intrahepatic Cholangiocarcinoma: An Update on Survival From Two Prospective Clinical Trials","volume":"31","author":"Konstantinidis I.","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"e_1_2_7_32_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global Trends in Mortality From Intrahepatic and Extrahepatic Cholangiocarcinoma","volume":"71","author":"Bertuccio P.","year":"2019","journal-title":"Journal of Hepatology"},{"issue":"2","key":"e_1_2_7_33_1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.soc.2013.10.004","article-title":"Intrahepatic Cholangiocarcinoma","volume":"23","author":"Brown K. M.","year":"2014","journal-title":"Surgical Oncology Clinics of North America"},{"issue":"2","key":"e_1_2_7_34_1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma\u2014Evolving Concepts and Therapeutic Strategies","volume":"15","author":"Ilyas S. I.","year":"2018","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"1","key":"e_1_2_7_35_1","first-page":"7","article-title":"Cancer Statistics, 2022","volume":"72","author":"Siegel R. L.","year":"2022","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"7","key":"e_1_2_7_36_1","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1245\/s10434-024-15187-y","article-title":"Outcomes of Hepatic Artery\u2010Based Therapies and Systemic Multiagent Chemotherapy in Unresectable Colorectal Liver Metastases: A Systematic Review and Meta\u2010Analysis","volume":"31","author":"Sugumar K.","year":"2024","journal-title":"Annals of Surgical Oncology"},{"issue":"2","key":"e_1_2_7_37_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s10637-020-01009-x","article-title":"Determinants of Pain in Advanced HCC Patients Recieving Hepatic Artery Infusion Chemotherapy","volume":"39","author":"Wu Z.","year":"2021","journal-title":"Investigational New Drugs"},{"issue":"1","key":"e_1_2_7_38_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jamcollsurg.2005.03.019","article-title":"Technical Complications and Durability of Hepatic Artery Infusion Pumps for Unresectable Colorectal Liver Metastases: An Institutional Experience of 544 Consecutive Cases","volume":"201","author":"Allen P. J.","year":"2005","journal-title":"Journal of the American College of Surgeons"},{"issue":"2","key":"e_1_2_7_39_1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.suc.2015.11.002","article-title":"Hepatic Artery Infusional Chemotherapy","volume":"96","author":"Lewis H. L.","year":"2016","journal-title":"Surgical Clinics of North America"},{"issue":"6","key":"e_1_2_7_40_1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/bjs.1800660603","article-title":"A New Look at the Arterial Supply of the Bile Duct in Man and Its Surgical Implications","volume":"66","author":"Northover J. M. A.","year":"1979","journal-title":"Journal of British Surgery"},{"issue":"4","key":"e_1_2_7_41_1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0025-6196(11)63706-3","article-title":"Ischemic Cholangitis","volume":"73","author":"Batts K. P.","year":"1998","journal-title":"Mayo Clinic Proceedings"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.70196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jso.70196","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.70196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T18:00:41Z","timestamp":1773597641000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.70196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/jso.70196"],"URL":"https:\/\/doi.org\/10.1002\/jso.70196","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"2025-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}